Decreased Expression of RNA-binding Motif Protein 3 Correlates with Tumour Progression and Poor Prognosis in Urothelial Bladder Cancer

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2013 Apr 10

PMID 23565664

Citations 27

Authors

Karolina Boman

Ulrika Segersten

Goran Ahlgren

Jakob Eberhard

Mathias Uhlen

Karin Jirstrom

Per-Uno Malmstrom

Affiliations

Soon will be listed here.

Abstract

Background: Low nuclear expression of the RNA-binding motif protein 3 (RBM3) has previously been found to be associated with poor prognosis in several cancer forms e.g. breast, ovarian, colorectal, prostate cancer and malignant melanoma. The aim of this study was to examine the prognostic impact of RBM3 expression in urinary bladder cancer.

Methods: Immunohistochemical RBM3 expression was examined in tumours from 343 patients with urothelial bladder cancer. Chi-square and Spearman's correlation tests were applied to explore associations between RBM3 expression and clinicopathological characteristics. The impact of RBM3 expression on disease-specific survival (DSS), 5-year overall survival (OS) and progression-free survival (PFS) was assessed by Kaplan-Meier analysis and Cox proportional hazards modelling.

Results: Reduced nuclear RBM3 expression was significantly associated with more advanced tumour (T) stage (p <0.001) and high grade tumours (p=0.004). Negative RBM3 expression was associated with a significantly shorter DSS (HR=2.55; 95% CI 1.68-3.86)) and 5-year OS (HR=2.10; 95% CI 1.56-2.82), also in multivariable analysis (HR=1.65; 95% CI 1.07-2.53 for DSS and HR=1.54; 95% CI 1.13-2.10 for 5-year OS). In patients with Ta and T1 tumours expressing reduced RBM3 levels, Kaplan-Meier analysis revealed a significantly shorter PFS (p=0.048) and 5-year OS (p=0.006).

Conclusion: Loss of RBM3 expression is associated with clinically more aggressive tumours and an independent factor of poor prognosis in patients with urothelial bladder cancer and a potentially useful biomarker for treatment stratification and surveillance of disease progression.

Citing Articles

Alternative splicing regulation and its therapeutic potential in bladder cancer.

Li L, Jin T, Hu L, Ding J Front Oncol. 2024; 14:1402350.

PMID: 39132499 PMC: 11310127. DOI: 10.3389/fonc.2024.1402350.

Long non-coding RNAs in cancer: multifaceted roles and potential targets for immunotherapy.

Kadian L, Verma D, Lohani N, Yadav R, Ranga S, Gulshan G Mol Cell Biochem. 2024; 479(12):3229-3254.

PMID: 38413478 DOI: 10.1007/s11010-024-04933-1.

RNA-Binding Proteins in Bladder Cancer.

Gao Y, Cao H, Huang D, Zheng L, Nie Z, Zhang S Cancers (Basel). 2023; 15(4).

PMID: 36831493 PMC: 9953953. DOI: 10.3390/cancers15041150.

RNA Binding Motif Protein 3 Promotes Cell Metastasis and Epithelial-Mesenchymal Transition Through STAT3 Signaling Pathway in Hepatocellular Carcinoma.

Zhang L, Zhang Y, Shen D, Chen Y, Feng J, Wang X J Hepatocell Carcinoma. 2022; 9:405-422.

PMID: 35592242 PMC: 9112182. DOI: 10.2147/JHC.S351886.

Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.

Wahlin S, Boman K, Moran B, Nodin B, Gallagher W, Karnevi E BMC Cancer. 2022; 22(1):131.

PMID: 35109796 PMC: 8811987. DOI: 10.1186/s12885-021-09168-7.

References

Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K . The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Pediatr Res. 2009; 67(1):35-41. DOI: 10.1203/PDR.0b013e3181c13326. View

Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M . RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol. 2011; 4(4):212-21. PMC: 3140008. DOI: 10.1593/tlo.11106. View

Masood S, Sriprasad S, Palmer J, Mufti G . T1G3 bladder cancer--indications for early cystectomy. Int Urol Nephrol. 2004; 36(1):41-4. DOI: 10.1023/b:urol.0000032688.37789.7c. View

Loehrer Sr P, Einhorn L, Elson P, Crawford E, Kuebler P, Tannock I . A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10(7):1066-73. DOI: 10.1200/JCO.1992.10.7.1066. View

Ehlen A, Brennan D, Nodin B, OConnor D, Eberhard J, Alvarado-Kristensson M . Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med. 2010; 8:78. PMC: 2936876. DOI: 10.1186/1479-5876-8-78. View

Sureban S, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri K . Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene. 2008; 27(33):4544-56. PMC: 2677646. DOI: 10.1038/onc.2008.97. View

Raab S, Grzybicki D, Vrbin C, Geisinger K . Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol. 2007; 127(6):946-53. DOI: 10.1309/XUVXFXMFPL7TELCE. View

Hjelm B, Brennan D, Zendehrokh N, Eberhard J, Nodin B, Gaber A . High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Proteomics Clin Appl. 2011; 5(11-12):624-35. DOI: 10.1002/prca.201100020. View

Soloway M, Lopez A, Patel J, Lu Y . Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer. 1994; 73(7):1926-31. DOI: 10.1002/1097-0142(19940401)73:7<1926::aid-cncr2820730725>3.0.co;2-q. View

10.

Jogi A, Brennan D, Ryden L, Magnusson K, Ferno M, Stal O . Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Mod Pathol. 2009; 22(12):1564-74. DOI: 10.1038/modpathol.2009.124. View

11.

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K . DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434(7035):864-70. DOI: 10.1038/nature03482. View

12.

Sievert K, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M . Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009; 27(3):295-300. PMC: 2694315. DOI: 10.1007/s00345-009-0395-z. View

13.

Sternberg C, Bellmunt J, Sonpavde G, Siefker-Radtke A, Stadler W, Bajorin D . ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2012; 63(1):58-66. DOI: 10.1016/j.eururo.2012.08.010. View

14.

Bartkova J, Rajpert-De Meyts E, Skakkebaek N, Lukas J, Bartek J . DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Int J Androl. 2007; 30(4):282-91. DOI: 10.1111/j.1365-2605.2007.00772.x. View

15.

Sternberg C . The treatment of advanced bladder cancer. Ann Oncol. 1995; 6(2):113-26. DOI: 10.1093/oxfordjournals.annonc.a059105. View

16.

Lebret T, Watson R, Molinie V, Poulain J, ONeill A, Fitzpatrick J . HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol. 2006; 51(1):161-6. DOI: 10.1016/j.eururo.2006.06.006. View

17.

Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M . Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study. J Transl Med. 2011; 9:114. PMC: 3156749. DOI: 10.1186/1479-5876-9-114. View

18.

von der Maase H, Hansen S, Roberts J, Dogliotti L, Oliver T, Moore M . Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17):3068-77. DOI: 10.1200/JCO.2000.18.17.3068. View

19.

Jonsson L, Gaber A, Ulmert D, Uhlen M, Bjartell A, Jirstrom K . High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagn Pathol. 2011; 6:91. PMC: 3195697. DOI: 10.1186/1746-1596-6-91. View

20.

Raghavan D, Shipley W, Garnick M, Russell P, Richie J . Biology and management of bladder cancer. N Engl J Med. 1990; 322(16):1129-38. DOI: 10.1056/NEJM199004193221607. View